Prescription medicine
Vepdegestrant Brand names: Veppanu
Vepdegestrant (Veppanu) is a prescription medicine with an FDA approval on record since 2026. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the vepdegestrant FDA label on DailyMed (effective June 12, 2026, Rigel Pharmaceuticals, Inc.); the NDA 219835 record on Drugs@FDA; every vepdegestrant label on DailyMed.
Highlights of the record
FDA label of June 12, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageVEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Forms and strengths
- 100 mg
- 200 mg
Tablet; film-coated tablet.
On the market
- Earliest approval on file
- May 1, 2026 Veppanu, Rigel Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- January 30, 2038 Veppanu tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 3 through July 30, 2026
What is vepdegestrant used for?
From the label: indications and usageVEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. […]
Source: FDA drug label (VEPPANU), Rigel Pharmaceuticals, Inc., effective June 12, 2026 (SPL set 484e21ba-8fe1-4c6d-b923-8ba4cf5b2f20), via openFDA; the full label on DailyMed
What does the patient leaflet for vepdegestrant say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while taking VEPPANU?Avoid taking St. John’s wort, eating grapefruit, or drinking grapefruit juice during treatment with VEPPANU.
From the patient leaflet: How should I store VEPPANU?Store VEPPANU at room temperature between 68°F to 77°F (20°C to 25°C). VEPPANU comes in a bottle with a child-resistant closure. Keep VEPPANU and all medicines out of the reach of children.
Source: FDA drug label (VEPPANU), Rigel Pharmaceuticals, Inc., effective June 12, 2026 (SPL set 484e21ba-8fe1-4c6d-b923-8ba4cf5b2f20), via openFDA; the full label on DailyMed
Is there a generic for vepdegestrant (Veppanu)?
No generic vepdegestrant is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 3 patents for Veppanu tablets: the compound patent runs to January 30, 2038. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2026 earliest approval on file
- 2038 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for vepdegestrant?
The FDA Adverse Event Reporting System holds 3 reports that list vepdegestrant among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Vepdegestrant side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other